Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 420

1.

Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.

Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, Ernst P; Canadian Network for Observational Drug Effect Studies..

BMJ. 2013 Mar 18;346:f880. doi: 10.1136/bmj.f880.

2.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

3.
4.

Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.

Heintjes EM, Penning-van Beest FJ, Plat AW, Meerding WJ, Webb K, Sturkenboom MC, Herings RM.

Pharmacotherapy. 2012 Jul;32(7):631-41. doi: 10.1002/j.1875-9114.2011.01086.x.

PMID:
22760692
5.

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.

Lewicki M, Ng I, Schneider AG.

Cochrane Database Syst Rev. 2015 Mar 11;(3):CD010480. doi: 10.1002/14651858.CD010480.pub2. Review.

PMID:
25758322
6.

Risk of incident diabetes among patients treated with statins: population based study.

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.

BMJ. 2013 May 23;346:f2610. doi: 10.1136/bmj.f2610. Erratum in: BMJ. 2013;347:f4356.

7.

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.

Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, Kosel BW, Saag MS, Kitahata MM, Crane HM.

Clin Infect Dis. 2011 Feb 1;52(3):387-95. doi: 10.1093/cid/ciq111. Epub 2010 Dec 28.

8.

The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.

García-Rodríguez LA, Massó-González EL, Wallander MA, Johansson S.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):943-52. doi: 10.1002/pds.1603.

PMID:
18425988
9.

The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.

Sarma A, Cannon CP, de Lemos J, Rouleau JL, Lewis EF, Guo J, Mega JL, Sabatine MS, O'Donoghue ML.

J Am Heart Assoc. 2014 May 1;3(3):e000784. doi: 10.1161/JAHA.114.000784.

10.
11.
13.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

14.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases.

Dormuth CR, Filion KB, Paterson JM, James MT, Teare GF, Raymond CB, Rahme E, Tamim H, Lipscombe L; Canadian Network for Observational Drug Effect Studies Investigators..

BMJ. 2014 May 29;348:g3244. doi: 10.1136/bmj.g3244.

15.

Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.

García Rodríguez LA, Herings R, Johansson S.

Pharmacoepidemiol Drug Saf. 2010 Dec;19(12):1218-24. doi: 10.1002/pds.2032. Epub 2010 Oct 4.

PMID:
20922707
16.

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.

Am J Cardiovasc Drugs. 2010;10(2):73-84. doi: 10.2165/10061630-000000000-00000.

PMID:
20136164
17.
18.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group..

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
19.

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group..

Am J Cardiol. 2007 Jun 1;99(11):1538-43. Epub 2007 Apr 16.

PMID:
17531577
20.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946

Supplemental Content

Support Center